指南与共识产科母胎医学

ACOG实践简报第207号:妊娠期血小板减少症

ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy.
指南 / 共识 · Obstet Gynecol · 2019-01-01

该实践简报针对妊娠期血小板减少症的诊断与管理进行重点修订,更新了妊娠期血小板减少症的新估计值、胎儿新生儿同种免疫性血小板减少症在后续妊娠中的复发风险,以及允许区域麻醉的血小板减少水平。血小板减少定义为血小板计数低于150×10^9/L,在分娩时发生于7-12%的妊娠中。

要点

  • 血小板减少定义为血小板计数低于150×10^9/L,分娩时发生于7-12%的妊娠。
  • 妊娠期血小板减少症为良性,不构成母胎风险;部分病因可致母胎并发症。
  • 本次修订更新了胎儿新生儿同种免疫性血小板减少症复发风险及区域麻醉血小板阈值信息。

核心结论

  • 本实践简报为针对性修订,反映妊娠期血小板减少症新估计值、胎儿新生儿同种免疫性血小板减少症后续妊娠复发风险及允许区域麻醉的血小板减少水平方面的有限信息变化。

研究设计与样本

  • 美国妇产科医师学会(ACOG)制定的实践简报,属于指南类文件,针对妊娠期血小板减少症的重点修订。

主要发现

  • 血小板减少定义为血小板计数低于150×10^9/L,在分娩时发生于7-12%的妊娠。
  • 妊娠期血小板减少症为良性,不构成母体或胎儿风险;部分病因可致母体和胎儿并发症。
  • 临床医生须权衡母胎出血并发症风险与诊断检查及侵入性干预的费用和并发症。

关键数值与推荐

  • 血小板减少定义为血小板计数低于150×10^9/L。
  • 血小板计数从10^9/μL转换为10^9/L的转换因子为1.0。
  • 分娩时血小板减少发生于7-12%的妊娠。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obstetricians frequently diagnose thrombocytopenia in pregnant women because platelet counts are included with automated complete blood cell counts obtained during routine prenatal screening (). Although most U.S. health care providers are trained using U.S. Conventional Units, most scientists, journals, and countries use Système International (SI) units. The laboratory results reported in U.S. Conventional Units can be converted to SI Units or vice versa by using a conversion factor. Given the conversion factor is 1.0, when converting from 10/μL to 10/L the platelet "count" does not seemingly change. Thrombocytopenia, defined as a platelet count of less than 150 × 10/L, is common and occurs in 7-12% of pregnancies at the time of delivery (). Thrombocytopenia can result from a variety of physiologic or pathologic conditions, several of which are unique to pregnancy. Some causes of thrombocytopenia are serious medical disorders that have the potential for maternal and fetal morbidity. In contrast, other conditions, such as gestational thrombocytopenia, are benign and pose no maternal or fetal risks. Because of the increased recognition of maternal and fetal thrombocytopenia, there are numerous controversies about obstetric management of this condition. Clinicians must weigh the risks of maternal and fetal bleeding complications against the costs and morbidity of diagnostic tests and invasive interventions. This Practice Bulletin is a targeted revision to reflect limited changes to information about new estimates for thrombocytopenia in pregnancy and the risk of recurrence of fetal-neonatal alloimmune thrombocytopenia in subsequent pregnancies, and to provide new information on the level of thrombocytopenia that permits regional anesthesia.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy. Obstet Gynecol. 2019. PMID: 30801473. doi:10.1097/AOG.0000000000003100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。